Navigation Links
Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer
Date:5/30/2009

- Phase 3 study has demonstrated that Induction Chemotherapy prior to ChemoRadiotherapy significantly increased time-to-treatment failure in comparison to standard ChemoRadiotherapy alone -

MADRID, May 30 /PRNewswire/ -- The Spanish Head and Neck Cancer Cooperative Group (TTCC) announced today that Induction Chemotherapy (IC) delivered prior to standard ChemoRadiotherapy (CRT), a treatment paradigm defined as sequential therapy, compared to upfront CRT alone, significantly prolonged Time-to-Treatment Failure (TTF) for patients with unresectable Locally Advanced Head and Neck Cancer (LAHNC). The endpoint of Time-to-Treatment Failure was defined as a composite of time-to-disease progression, -to-surgery or other cancer-related treatments, -to-drop-out due to an adverse event, and to death from any cause.

Final results (abstract #6009) from the Phase 3 randomized study were presented by Prof. Ricardo Hitt, of the University Hospital 12 de Octubre, Madrid, in an oral presentation at the 2009 annual meeting of the American Society of Clinical Oncology (ASCO). The results of this study have also been selected for inclusion in the Best of ASCO(R) program. The Best of ASCO(R) is an educational initiative that condenses highlights from ASCO's Annual Meeting, with the objective of increasing global access to cutting-edge science that is relevant and significant in oncology today.

This study enrolled 439 patients with Locally Advanced Head and Neck Cancer with good performance status, who were randomly assigned to receive standard CRT (cisplatin and fractionated radiation) versus the same treatment preceded by IC, which consisted of cisplatin plus 5-fluorouracil (5-FU) with or without Taxotere(R) (docetaxel) Injection Concentrate. The study was designed to compare the results of those patients who received IC prior to CRT (sequential therapy) and patients who received CRT alone.

The sequential therapy of adding IC to CRT improved Time-to-Treatment Failure (TTF) from 5.0 months to 12.5 months (p< 0.0001), a 7.5 month increase. Furthermore, a secondary endpoint of loco-regional control, was observed in 61.5% of the patients treated with the sequential strategy (IC+CRT) compared to 44.5% of those patients treated with CRT alone (p=0.002).

The most frequent severe (grade 3-4) adverse reactions were stomatitis (44% for IC+CRT vs. 31% for CRT) and febrile neutropenia (10% for IC+CRT vs. 1% for CRT). Other adverse events included neutropenia and asthenia.

"These study results illustrate that this complex disease deserves a rational and comprehensive management strategy to overcome its pathologic mechanism and the inherent possibility of failure of clinical control," said Prof. Ricardo Hitt, MD, PhD, the study principal investigator, from Medical Oncology Service of the University Hospital 12 de Octubre, Madrid, Spain.

Every year more than 640,000 people worldwide are diagnosed with head and neck cancer, and an estimated more than 350,000 will die from the disease. Head and neck cancer is a group of tumors that mostly arise in the cells that line the mucosal surfaces, giving rise to squamous cell carcinoma in the head and neck area, such as the mouth, tongue, tonsils, voice box and throat.

"This trial showed that adding Induction Chemotherapy to ChemoRadiotherapy increased failure-free survival while significantly increasing local control in patients with advanced unresectable head and neck cancer," said Fadlo Khuri, MD, Professor and Roberto Goizueta Chair of Hematology and Medical Oncology at Emory University, Atlanta, GA, USA. Dr. Khuri, a renowned head and neck cancer expert, also added: "These data may help define and clarify standard approaches to the treatment of patients with advanced unresectable disease."

About the Spanish Head and Neck Cancer Cooperative Group, TTCC

Grupo Espanol de Tratamiento de Tumores de Cabeza y Cuello (TTCC) is a Spanish non-profit scientific cooperative group fully devoted to head and neck cancer. The group is comprised of medical oncologists, who belong to the Spanish Society of Medical Oncology (SEOM) as well as of other health professionals related to head and neck cancer research and treatment. The main Spanish Head and Neck Cancer Cooperative Group objectives are to promote basic, epidemiological and clinical research, and to provide education to doctors and patients and dissemination of information in the field of head and neck cancer to the Spanish general population.

    Contact TTCC:
    Pr. Ricardo Hitt: + 34 629 26 28 33

    Tara Dimilia: 908-884-7024


'/>"/>
SOURCE Spanish Head and Neck Cancer Cooperative Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients
2. Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months
3. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
4. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
5. Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
6. Agendias MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
7. Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies
8. Photos: Peptides Discovered to Alleviate Chemotherapy Side Effects
9. Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkins Lymphoma
10. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
11. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 29, 2017  Designers of primary cell wearable medical ... by 50% and extend battery life with the MAX20310 ... circuit (PMIC) from Maxim Integrated Products, Inc. (NASDAQ: ... input voltage of just 0.7V for new high-energy density ... as well as the more common Alkaline battery architecture. ...
(Date:3/29/2017)... , USA, March 29, 2017 Stryker ... that Cares by People magazine, in partnership with Great ... 50 companies on the list. This list highlights the ... have succeeded in business while also demonstrating respect, compassion ... environment.  To determine the companies on ...
(Date:3/29/2017)... March 29, 2017 /PRNewswire/ - Medicure Inc. ("Medicure") (TSXV:MPH, ... results for the year ended December 31, 2016 ... The results are being released later than the ... will include the operations and balances of Apicore ... This release and filing date meets TSX Venture ...
Breaking Medicine Technology:
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... services with or without a referral to new patients from Burnaby, BC. Patients ... or other full mouth reconstruction services, can see the esteemed team at Wall ...
(Date:3/29/2017)... ... March 29, 2017 , ... Patients interested in receiving ... from Dr. Jamie Cameron, with or without a referral. The FASTBRACES system is ... Depending on each patient’s case, treatment with the FASTBRACES system could be completed ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... it continues developing an ANSI-approved, consensus-based American National Standard for Good Manufacturing ... publish the first ANSI-approved GMP standard for dietary supplements this spring, is ...
(Date:3/29/2017)... ... 29, 2017 , ... Altima Technologies, Inc., the maker of ... center assets and audio-video devices has recently updated its Visio Stencils library with ... and download shapes and stencils from http://www.VisioStencils.com. , New devices were ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... oral braces. "The rubber bands used in conjunction with my braces always rubbed ... to design a way to prevent this problem." The O.B.S. was the result ...
Breaking Medicine News(10 mins):